tbuckley/cabot-search huggingface dataset:
Consent difficult in paediatric oncology
Authors: O B Eden
Journal: BMJ (1994)

deciding what to tell patients should be left to the clinical judgment of the doctor.The main problem with this is that doctors have a poor track record in assessing the information needs and emotional needs of patients4 and judging their own skills in communication.' Randomised controlled trials are generally considered to be the best antidote to clinical uncertainty.When there is behavioual uncertainty, such as over how to inform patients about trials, randomised controlled trials should again be the method of choice.Such studies would compare the effects on different groups of patients of different methods of informing them about trials.These methods could vary in the amount and type of information provided, the training of the person providing the information, and the period over which information was given and decisions sought.The impact of these different approaches on emotions, thinking, and decisions could then be assessed.Tobias and Souhami may be correct in their clinical impressions that the practice of obtaining informed consent serves ethical principles more than the needs of patients.These impressions should be tested experimentally.
Outcome of Patients Receiving Venetoclax for Chronic Lymphocytic Leukemia (CLL) in Real-Life Clinical Practice: Results of the French ATU Program on Behalf of the Filo Group
Authors: Florian Bouclet, Anne Calleja, Marie-Sarah Dilhuydy, Sandy Amorim, Florence Cymbalista, Charles Herbaux, Sophie de Guibert, Damien Roos-Weil, Benedicte Hivert, Thérèse Aurran, Jehan Dupuis, Anaise Blouet, Emmanuelle Tchernonog, Kamel Laribi, Natalia Dmytruk, Pierre Morel, Anne-Sophie Michallet, Caroline Dartigeas, Laure Farnault, Anne Lavaud, Isabelle Plantier, Jacques-Olivier Bay, Olivier Tournilhac, Alain Jacques Delmer, Pierre Feugier, Loic Ysebaert, Romain Guieze
Journal: Blood (2018)
TCT-475 Diagnostic and Prognostic Role of Nitroglycerin-Induced Dilation in Patients With Suspected Vasospastic Angina Comparison With Ergonovine Provocation Test
Authors: Seung Hwan Han, Minsu Kim, Albert Jongwook Yu, Pyung Chun Oh, Soon Yong Suh, Kyounghoon Lee, Woong Chol Kang, Taehoon Ahn
Journal: Journal of the American College of Cardiology (2019)
Biologics beyond Anti-TNF Agents for Ulcerative Colitis — Efficacy, Safety, and Cost?
Authors: Richard J. Farrell
Journal: New England Journal of Medicine (2019)

Ulcerative colitis typically manifests in young adults in their 20s and 30s and can progress from mild asymptomatic rectal inflammation to debilitating extensive colitis resulting in frequent bloody stools, systemic symptoms, and colorectal cancer.1 Approximately one third of patients with distal ulcerative colitis at the time of diagnosis will have more extensive colitis by 10 years,2 and 10 to 15% of patients with ulcerative colitis will ultimately require a colectomy.3-5 Biologic agents are recommended for patients with moderate-to-severe ulcerative colitis who have not had a response to conventional therapies such as aminosalicylates, corticosteroids, or immunomodulators or who cannot receive such . . .
TCT-690 Initial Deployment Orientation of ACURATE-neo THV and Final Commissural Alignment: A Pilot Study on Optimizing Post-Procedural Coronary Access
Authors: Andreas Fuchs, Eisha Gupta, Syed Zaid, Klaus Fuglsang Kofoed, Lars Sondergaard, Ole De Backer, Gilbert Tang
Journal: Journal of the American College of Cardiology (2019)
TCT-493 Epidemiology of In-Hospital Cardiac Arrest Complicating Non–ST-Segment Elevation Myocardial Infarction Receiving Early Coronary Angiography
Authors: Saraschandra Vallabhajosyula, Saarwaani Vallabhajosyula, Barry Burstein, Bradley Ternus, Pranathi Sundaragiri, Roger White, Gregory Barsness, Jacob Jentzer
Journal: Journal of the American College of Cardiology (2019)
Abstract 10541: Improved Benefit Risk Profile of Rivaroxaban in a MARINER-Like Subpopulation of the MAGELLaN Study
Authors: Alex C Spyropoulos, Alexander T Cohen, Concetta Lipardi, Jianfeng Xu, Eunyoung Suh, Yoriko De Sanctis, Theodore E Spiro, Elliot S Barnathan, Gary E Raskob
Journal: Circulation (2018)

Introduction: The MAGELLaN Study was a randomized double-blind active (enoxaparin) and placebo controlled study of rivaroxaban (10mg QD) in medically ill hospitalized subjects treated in hospital a...
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
Authors: N.W. Clarke, A. Ali, F.C. Ingleby, A. Hoyle, C.L. Amos, G. Attard, C.D. Brawley, J. Calvert, S. Chowdhury, A. Cook, W. Cross, D.P. Dearnaley, H. Douis, D. Gilbert, S. Gillessen, R.J. Jones, R.E. Langley, A. MacNair, Z. Malik, M.D. Mason, D. Matheson, R. Millman, C.C. Parker, A.W.S. Ritchie, H. Rush, J.M. Russell, J. Brown, S. Beesley, A. Birtle, L. Capaldi, J. Gale, S. Gibbs, A. Lydon, A. Nikapota, A. Omlin, J.M. O'Sullivan, O. Parikh, A. Protheroe, S. Rudman, N.N. Srihari, M. Simms, J.S. Tanguay, S. Tolan, J. Wagstaff, J. Wallace, J. Wylie, A. Zarkar, M.R. Sydes, M.K.B. Parmar, N.D. James
Journal: Annals of Oncology (2019)

BackgroundSTAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients.MethodsWe randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional.ResultsBetween 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n = 724) or SOC + docetaxel (n = 362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%) high metastatic burden. Median follow-up was 78.2 months. There were 494 deaths on SOC (41% more than the previous report). There was good evidence of benefit of docetaxel over SOC on OS (HR = 0.81, 95% CI 0.69–0.95, P = 0.009) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P = 0.827). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR = 0.66, 95% CI 0.57–0.76, P < 0.001) and progression-free survival (HR = 0.69, 95% CI 0.59–0.81, P < 0.001) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P > 0.5 in each case). There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression).ConclusionsThe clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naïve prostate cancer patients regardless of metastatic burden.
TCT-495 Global Health: Telemedicine-Guided AMI Management
Authors: Sameer Mehta, Roberto Botelho, Jamil Cade, Marco Perin, Mauricio Prudente, Ricardo Cavalcanti, Cesar Dusilek, Rodolfo Cardoso, Nabil Hamdan, Luis Ignacio Calderon, Marco Alcocer-Gamba, Juan Carlos Perez Alva, Alfredo Estrada, Manuel De Los Rios Ibarra, Alejandro Ricalde, Alejandra Frauenfelder, Daniel Vieira, Mariana Ceschim, Rodrigo Jacobucci, Estefania Cecilio, Maria Acosta, Camila Funatsu, Isabella Vallenilla, José Aguilar, Daniela Bou Daher, Akhil Vaid
Journal: Journal of the American College of Cardiology (2019)
A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma
Authors: Darrell J White, Nizar J. Bahlis, Christopher P. Venner, Gary J Schiller, Cristina J. Gasparetto, Heather J. Sutherland, Michael Sebag, Suzanne Lentzsch, Rami Kotb, William Bensinger, Brea C. Lipe, Christine I Chen, Aldo Del Col, Michael G. Kauffman, Sharon Shacham, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, Richard LeBlanc
Journal: Blood (2017)
TCT-614 Predictive &amp; Prognostic Value of Serum Neutrophil Gelatinase-Associated Lipocalin for Contrast-Induced Acute Kidney Injury and Long-Term Clinical Outcomes After Percutaneous Coronary Intervention
Authors: Ik Jun Choi, Eun Ho Choo, Sungmin Lim
Journal: Journal of the American College of Cardiology (2019)
TCT-653 Intravascular Lithotripsy for Lesion Preparation in Calcified Coronary Lesions: First Data of Prospective, Observational Multicenter Registry
Authors: Adem Aksoy, Carlos Salazar, Sebastian Zimmer, Javier Escaned, Georg Nickenig, Jan-Malte Sinning, Nikos Werner
Journal: Journal of the American College of Cardiology (2019)
TCT-506 LATIN - STEMI Prototype for Developing Countries
Authors: Sameer Mehta, Roberto Botelho, Jamil Cade, Marco Perin, Mauricio Prudente, Ricardo Cavalcanti, Cesar Dusilek, Rodolfo Cardoso, Nabil Hamdan, Luis Ignacio Calderon, Marco Alcocer-Gamba, Juan Carlos Perez Alva, Alfredo Estrada, Manuel De Los Rios Ibarra, Alejandro Ricalde, Alejandra Frauenfelder, Daniel Vieira, Gladys Pinto, Lorena Pisana, Jorge Mazzini, Anibal Munguia, Maria Acosta, Maria Marin, Isabella Vallenilla, Carlos Peña, Maritza Luna
Journal: Journal of the American College of Cardiology (2019)
TCT-408 Impact of Dedicated Dual Antiplatelet Therapy With Low-Dose Prasugrel on Mid-Term Vascular Response After Everolimus-Eluting Stent Implantation
Authors: Takayoshi Toba, Toshiro Shinke, Hiromasa Otake, Yoichiro Sugizaki, Ryo Takeshige, Hiroyuki Onishi, Akira Nagasawa, Hiroyuki Kawamori, Akira Matsuura, Takayuki Ishihara, Daisuke Matsumoto, Nobuaki Igarashi, Takatoshi Hayashi, Yoshinori Yasaka, Makoto Kadotani, Takashi Fujii, Junya Shite, Masaharu Okada, Takashi Sakakibara, Ken-ichi Hirata
Journal: Journal of the American College of Cardiology (2019)
AL Amyloidosis for the Cardiologist and Oncologist
Authors: Ronald M. Witteles, Michaela Liedtke
Journal: JACC CardioOncology (2019)

AL amyloidosis results from clonal production of immunoglobulin light chains, most commonly arising from a clonal plasma cell disorder. Once considered a nearly uniformly fatal disease, prognosis has improved markedly over the past 15 years, predominantly because of advances in light chain suppressive therapies. Cardiac deposition of amyloid fibrils is common, and the severity of cardiac involvement remains the primary driver of prognosis. Improvements in chemotherapy/immunotherapy have prompted a reassessment of the role of advanced cardiac therapies previously considered contraindicated in most patients, including the role of implantable cardioverter-defibrillators and cardiac transplantation. This state-of-the-art review highlights the current state of the field, including diagnosis, prognosis, and hematologic- and cardiac-specific therapies.
TCT-78 Transcatheter Aortic Valve Replacement in Patients With Large and Extra-Large Aortic Annuli: Hemodynamic Performance of New-Generation Balloon- and Self-Expandable Aortic Valves.
Authors: German Armijo Ortiz, Gilbert Tang, Nynke Kooistra, Marina Urena, Alfredo Nunes Ferreira Neto, Stefan Toggweiler, Ignacio Amat-Santos, Hasan Ahmad, Jose Tafur Soto, Ander Regueiro, Gabriela Tirado-Conte, Angela McInerney, Mohammed Ahmed, Dominique Himbert, Fabian Nietlispach, Pieter Stella, George Dangas, Carlos Macaya, Josep Rodés-Cabau, Luis Nombela-Franco
Journal: Journal of the American College of Cardiology (2019)
Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets
Authors: Carla Mottini, Francesco Napolitano, Zhongxiao Li, Xin Gao, Luca Cardone
Journal: Seminars in Cancer Biology (2019)

Despite huge efforts made in academic and pharmaceutical worldwide research, current anticancer therapies achieve effective treatment in a limited number of neoplasia cases only. Oncology terms such as big killers - to identify tumours with yet a high mortality rate - or undruggable cancer targets, and chemoresistance, represent the current therapeutic debacle of cancer treatments. In addition, metastases, tumour microenvironments, tumour heterogeneity, metabolic adaptations, and immunotherapy resistance are essential features controlling tumour response to therapies, but still, lack effective therapeutics or modulators. In this scenario, where the pharmaceutical productivity and drug efficacy in oncology seem to have reached a plateau, the so-called drug repurposing - i.e. the use of old drugs, already in clinical use, for a different therapeutic indication - is an appealing strategy to improve cancer therapy. Opportunities for drug repurposing are often based on occasional observations or on time-consuming pre-clinical drug screenings that are often not hypothesis-driven. In contrast, in-silico drug repurposing is an emerging, hypothesis-driven approach that takes advantage of the use of big-data. Indeed, the extensive use of -omics technologies, improved data storage, data meaning, machine learning algorithms, and computational modeling all offer unprecedented knowledge of the biological mechanisms of cancers and drugs' modes of action, providing extensive availability for both disease-related data and drugs-related data. This offers the opportunity to generate, with time and cost-effective approaches, computational drug networks to predict, in-silico, the efficacy of approved drugs against relevant cancer targets, as well as to select better responder patients or disease' biomarkers. Here, we will review selected disease-related data together with computational tools to be exploited for the in-silico repurposing of drugs against validated targets in cancer therapies, focusing on the oncogenic signaling pathways activation in cancer. We will discuss how in-silico drug repurposing has the promise to shortly improve our arsenal of anticancer drugs and, likely, overcome certain limitations of modern cancer therapies against old and new therapeutic targets in oncology.
TCT-577 Intensive Training and Real-Time Quality Control by a Core Laboratory Substantially Improves Physiology Measurements: Lessons From DEFINE-PCI
Authors: Mitsuaki Matsumura, Akiko Maehara, Justin Davies, Gautam Kumar, Andrew Sharp, Habib Samady, Arnold Seto, Ziad Ali, Gregg Stone, Manesh Patel, Allen Jeremias
Journal: Journal of the American College of Cardiology (2019)
Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Authors: Marin H Kollef, Martin Nováček, Ülo Kivistik, Álvaro Réa-Neto, Nobuaki Shime, Ignacio Martin-Loeches, Jean-François Timsit, Richard G Wunderink, Christopher J Bruno, Jennifer A Huntington, Gina Lin, Brian Yu, Joan R Butterton, Elizabeth G Rhee
Journal: The Lancet Infectious Diseases (2019)
TCT-517 The KAsH Score Predicts Long-Term Mortality After Acute Myocardial Infarction
Authors: Joel Monteiro, João Sousa, Flávio Mendonça, Ricardo Rodrigues, Micaela Rodrigues Neto, Marco Serrao, Bruno Silva, Ana Paula Faria, Drumond Freitas, Eva Henriques, Maria Isabel Mendonça
Journal: Journal of the American College of Cardiology (2019)
TCT-216 Contemporary Characteristics and Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusion in Japan: Comparison Between 2 Major Japanese Multicenter Registries
Authors: Shunsuke Matsuno, Maoto Habara, Toshiya Muramatsu, Koichi Kishi, Makoto Mutoh, Yuji Oikawa, Masahisa Yamane, Masami Sakurada, Masatoshi Miyahara, Etsuo Tsuchikane
Journal: Journal of the American College of Cardiology (2019)
TCT-230 Myocardial Ischemia Is Present and Mostly Reversible in Patients With a Chronic Total Occlusion and a Viable Perfusion Territory: The DISTAL CTO Study
Authors: Peter Kayaert, Mathieu Coeman, Benny Drieghe, Johan Bennett, Joseph Dens, Claudiu Ungureanu, Yoann Bataille, Steven Haine
Journal: Journal of the American College of Cardiology (2019)
Reducing Gun Violence Using Alcohol-Related Convictions
Authors: Elinore Kaufman, Christopher N. Morrison, Charles C. Branas
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
STUDIES IN RODENT POLIOMYELITIS
Authors: Claus W. Jungeblut, Murray Sanders, Rose R. Feiner
Journal: The Journal of Experimental Medicine (1942)

1. SK murine virus maintained over more than 200 serial mouse passages increased in virulence for mice from an initial intracerebral titer of about 1:1 million to a maximum titer of not less than 1:1 billion dilution activity. 2. Following intracerebral injection with murine virus of remote mouse passages, 5 of 13 rhesus monkeys developed a characteristic encephalitic syndrome. Repeated intravenous injection of massive doses of virus caused localized flaccid paralysis in 2 of 14 monkeys. 3. Intracerebral injection of graded doses of murine virus into mice of different age groups caused fatal paralysis in young and old animals alike. Infection with small doses of virus by peripheral routes, while uniformly fatal to young mice, was followed by survival of almost half of the old mice. 4. The incubation period of the disease in young mice infected intracerebrally with a standard dose of murine virus, when studied throughout the period of 1 year, was found considerably lengthened during the summer months. 5. Cross neutralization tests furnished no evidence for any serological relationship between SK murine virus and lymphocytic choriomeningitis virus. Theiler's virus was found to be neutralizable by antimurine horse serum and, to a lesser extent, by concentrated antipoliomyelitis horse serum; however, such inactivation, in both cases, was distinctly inferior to that occurring with SK murine virus. On the other hand, no neutralization whatsoever was obtained between SK murine virus and normal adult mouse serum, whereas the same serum completely neutralized Theiler's virus. Mice surviving infection with Theiler's virus, though acquiring immunity to this virus, remained fully susceptible to reinfection with SK murine virus. 6. Neutralization tests with SK murine virus against poliomyelitis-convalescent monkey sera gave irregular results, but neutralization of murine virus occurred regularly with a hyperimmune antipoliomyelitis horse serum. Hyperimmune antimurine horse and rabbit sera, on the other hand, failed to inactivate three strains of monkey poliomyelitis virus (SK, RMV, Aycock) by intracerebral tests in monkeys. The same sera inactivated murine virus in mice by intraperitoneal, but not by intracerebral injection of virus-serum mixtures. 7. The identity of SK murine virus and its relation to other rodent strains of poliomyelitis virus is discussed on the basis of the available data.
Trends in Survival After Pediatric In-Hospital Cardiac Arrest in the United States
Authors: Mathias J. Holmberg, Sebastian Wiberg, Catherine E. Ross, Monica Kleinman, Anne Kirstine Hoeyer-Nielsen, Michael W. Donnino, Lars W. Andersen
Journal: Circulation (2019)

Background: Cardiac arrest in hospitalized children is associated with poor outcomes, but no contemporary study has reported whether the trends in survival have changed over time. In this study, we examined temporal trends in survival for pediatric patients with an in-hospital pulseless cardiac arrest and pediatric patients with a nonpulseless cardiopulmonary resuscitation event from 2000 to 2018. Methods: This was an observational study of hospitalized pediatric patients (≤18 years of age) who received cardiopulmonary resuscitation from January 2000 to December 2018 and were included in the Get With The Guidelines-Resuscitation registry, a United States–based in-hospital cardiac arrest registry. The primary outcome was survival to hospital discharge, and the secondary outcome was return of spontaneous circulation (binary outcomes). Generalized estimation equations were used to obtain unadjusted trends in outcomes over time. Separate analyses were performed for patients with a pulseless cardiac arrest and patients with a nonpulseless event (bradycardia with poor perfusion) requiring cardiopulmonary resuscitation. A subgroup analysis was conducted for shockable versus nonshockable initial rhythms in pulseless events. Results: A total of 7433 patients with a pulseless cardiac arrest and 5751 patients with a nonpulseless event were included for the analyses. For pulseless cardiac arrests, survival was 19% (95% CI, 11%–29%) in 2000 and 38% (95% CI, 34%–43%) in 2018, with an absolute change of 0.67% (95% CI, 0.40%–0.95%; P &lt;0.001) per year, although the increase in survival appeared to stagnate following 2010. Return of spontaneous circulation also increased over time, with an absolute change of 0.83% (95% CI, 0.53%–1.14%; P &lt;0.001) per year. We found no interaction between survival to hospital discharge and the initial rhythm. For nonpulseless events, survival was 57% (95% CI, 39%–75%) in 2000 and 66% (95% CI, 61%–72%) in 2018, with an absolute change of 0.80% (95% CI, 0.32%–1.27%; P =0.001) per year. Conclusions: Survival has improved for pediatric events requiring cardiopulmonary resuscitation in the United States, with a 19% absolute increase in survival for in-hospital pulseless cardiac arrests and a 9% absolute increase in survival for nonpulseless events between 2000 and 2018. However, survival from pulseless cardiac arrests appeared to have reached a plateau following 2010.
Compound Application of Thalidomide and Recombinant Human Interferon-α-1b, Interleukin-2 in Different Disease Status of Acute Myeloid Leukemia a Multi-Center Prospective Study of a New Combination of Old Drugs
Authors: Lin Chen, Ruihua Mi, Xudong Wei, Qingsong Ying, Fangfang Yuan, Lijie Liang, Mengjuan Li, Delong Liu, Yongping Song
Journal: Blood (2018)
TCT-632 Complete Revascularization of Multivessel Coronary Artery Disease Does Not Improve Clinical Outcome in ST-Segment Elevation Myocardial Infarction Patients With Diabetes Mellitus
Authors: Hak Seung Lee, You Jeong Ki, Jeehoon Kang, Chengbin Zheng, Kyung Woo Park, Jiesuck Park, Tae-Min Rhee, Jung-Kyu Han, Han-Mo Yang, Hyun-Jae Kang, Bon-Kwon Koo, Hyo-Soo Kim
Journal: Journal of the American College of Cardiology (2019)
Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score Predicts Non-Relapse Mortality (NRM) and Overall Survival (OS) in Multiple Myeloma Patients Undergoing Intensive Preparative Regimen with Autologous Stem Cell Transplantation (ASCT) Followed By Maintenance Therapy Using Novel Agents
Authors: Kalyan Nadiminti, Umar Farooq, Lindsay Dozeman, Sarah Mott, Guido J. Tricot, Yogesh Jethava, Margarida Silverman
Journal: Blood (2017)